Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial - 02/09/11
The Australasian Multicentre Trial Group*
Abstract |
Background: Superficial basal cell carcinoma (sBCC) is an increasingly common tumor in fair-skinned populations throughout the world. Imiquimod, an immune response modifier that induces cytokines including interferons, has been shown in preliminary studies to have an effect when applied topically to BCC. Objective: We conducted a multicenter, randomized, open-label dose-response trial of imiquimod 5% cream in the treatment of primary sBCC assessing efficacy and safety of different dose regimens. Methods: Ninety-nine patients were randomized to 6 weeks' application of imiquimod in 1 of 4 treatment regimens: twice every day, once every day, twice daily 3 times/week, once daily 3 times/week. The treatment site was excised and examined histologically 6 weeks after cessation of imiquimod. Results: Intention-to-treat analysis revealed 100% (3/3) histologic clearance in the twice-daily regimen, 87.9% (29/33) clearance in the once every day regimen, 73.3% (22/30) clearance in the twice-daily 3 times/week regimen, and 69.7% (23/33) clearance in the once-daily 3 times/week regimen. Dose-related inflammatory skin reactions at the site of application were common. The majority were well tolerated and only 1 patient withdrew from the trial as a result of a medication-related skin reaction. Conclusion: Imiquimod 5% cream appears to have potential as a patient-administered treatment option in sBCC. (J Am Acad Dermatol 2001;44:807-13.)
Le texte complet de cet article est disponible en PDF.Plan
This study was initiated by and supported with a grant from 3M Pharmaceuticals, St Paul, Minn. |
|
Mark Amies, James Bryden, Terry Fox, and Mary Owens are all employees of 3M Pharmaceuticals; Robin Marks, Kurt Gebauer, Stephen Shumack, and the other members of the Australasian Multi-Centre Trial Group have no corporate affiliations with 3M Pharmaceuticals. |
|
*The Australasian Multicentre Trial Group: Drs Nicholas Birchall, Geoffrey Cains, Judith Cole, Kurt Gebauer, Robin Marks, Christopher Quirk, Stephen Shumack, Rodney Sinclair, Karen Stapleton, Alan Watson. Dermatopathologists: Drs Steven Kossard, Peter Heenan. |
|
Reprint requests: Professor Robin Marks, Department of Dermatology, St Vincent's Hospital, 41 Victoria Parade, Fitzroy 3065, Victoria, Australia. |
|
♢ | J Am Acad Dermatol 2001;44:807-13 |
Vol 44 - N° 5
P. 807-813 - mai 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?